You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR3 Genetic Alterations

Showing 1 - 25 of 9,935
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)

Recruiting
  • Gastrointestinal Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Dec 7, 2022

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • New York, New York
  • +2 more
Jan 31, 2023

Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer Trial in Worldwide (Infigratinib, Placebo)

Recruiting
  • Upper Tract Urothelial Carcinomas
  • Urothelial Bladder Cancer
  • Tucson, Arizona
  • +133 more
Apr 25, 2022

Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose

Completed
Has Results
  • Solid Tumor
  • Derazantinib low dose range
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Mar 7, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter Trial in Spain, United States (PRN1371)

Terminated
  • Solid Tumors
  • Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
  • San Francisco, California
  • +11 more
Dec 23, 2020

Cholangiocarcinoma,Adult Trial (3D185)

Not yet recruiting
  • Cholangiocarcinoma,Adult
  • (no location specified)
Sep 2, 2021

Urothelial Carcinoma Trial in Shanghai (AZD4547)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Oct 20, 2021

Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders Trial (ARQ 092)

No longer available
  • Proteus Syndrome
  • +2 more
  • ARQ 092
  • (no location specified)
Jul 31, 2021

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

FGFR Testing by Either ctDNA Blood Testing or Standard Tumor

Recruiting
  • Metastatic Bladder Cancer
  • Metastatic Urothelial Carcinoma
  • FGFR Testing
  • Calgary, Alberta, Canada
  • +6 more
Nov 8, 2023

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +23 more
  • Birmingham, Alabama
  • +166 more
Feb 2, 2023

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Recruiting
  • Bladder Cancer
  • +12 more
  • Raleigh, North Carolina
    xCures Virtual Site
Sep 20, 2021

Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma Trial in Australia, United States (Drug ICP-192)

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • Drug ICP-192
  • Tucson, Arizona
  • +8 more
Jan 28, 2022

Malignant Tumor Trial in Ann Arbor, Columbus (ponatinib HCl, laboratory biomarker analysis)

Unknown status
  • Malignant Neoplasm
  • ponatinib hydrochloride
  • laboratory biomarker analysis
  • Ann Arbor, Michigan
  • +1 more
Feb 14, 2020

Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, Autosomal Dominant Polycystic Kidney Trial in

Not yet recruiting
  • Atypical Hemolytic Uremic Syndrome
  • +3 more
  • Skin biopsy
  • Ranica, BG, Italy
    Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Da
Aug 9, 2023

Glioblastoma, Adult-type Diffuse Gliomas Trial in Worldwide (Pemigatinib)

Recruiting
  • Glioblastoma
  • Adult-type Diffuse Gliomas
  • Beverly Hills, California
  • +83 more
Jul 25, 2022